Congress Materials – American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM 2024)
2024 American Association of Neuromuscular & Electrodiagnostic Medicine | Oct 15-18 | Savannah, GA
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Adverse pregnancy outcomes in myasthenia gravis: A retrospective cohort study in a US health insurance claims database
Melanie H. Jacobson, Rupa Makadia, John Sheehan, Nathan Hall, Jill Hardin, Sicong Huang, Ran Sun, Rebecca Zaha, Alexis A. Krumme
Assessing the suitability of the Neuro-QoL Fatigue to evaluate fatigue in patients living with Myasthenia Gravis
Sheryl Pease, Kayla Scippa
Efficacy and Safety of Nipocalimab in Patients with Generalized Myasthenia Gravis: Topline Results from the Double-Blind, Placebo-Controlled, Randomized Phase 3 Vivacity-MG3 Study
Tuan Vu, Carlo Antozzi, Sindhu Ramchandren, Richard J. Nowak, Constantine Farmakidis, Vera Bril, Jan De Bleecker, Huan Yang, Eduard Minks, Jin-Sung Park, Mariusz Grudniak, Marek Smilowski, Teresa Sevilla, Sarah Hoffmann, Kumaraswamy Sivakumar, Eriene Youssef, Panna Sanga, Keith Karcher, Yaowei Zhu, Leona E. Ling, Hong Sun
Factors influencing exacerbations and crisis in generalized myasthenia gravis: Findings from a claims database study
Louis Jackson, Zhiwen Liu, Jacqueline Pesa, Alicia K Campbell, Zia Choudhry, Alberto E Batista, Qian Cai, Nizar Souayah
Interim results for Myasthenia Gravis-Resource Utilization, Epidemiology, Survival & Treatment Patterns (MG-REST) study in Ontario, Canada
Carolina Barrnett-Tapia, Kobina Quansah, Aysegul Erman, Ryan Ng, Nikhil Nath, Arushi Sharma
Leveraging AI to characterize mental health experiences throughout the Myasthenia Gravis diagnosis journey
Raghav Govindarajan, Rachelle D. Rodriguez, Zia Choudhry, Caroline Brethenoux, Jacqui Pesa, Sindhu Ramchandren, Nolan Campbell, Kavita Gandhi, Kristin Heerlein, Nizar Souayah, Ashley E.L. Anderson
Perinatal treatment patterns in myasthenia gravis
Melanie H. Jacobson, Rupa Makadia, Anna Ostropolets, John Sheehan, Sicong Huang, Rebecca Zaha, Alexis A. Krumme
Safety and effectiveness of nipocalimab in adolescent participants in the open label Phase 2/3 VIBRANCE-MG clinical study
Jonathan Strober, Shawn Black, Sindhu Ramchandren, Saunder Bernes, Akiyuki Uzawa, Yasuhiro Kimoto, Keiko Ishigaki, Tuan Vu, Dan Huang, Yaowei Zhu, Hong Sun
Treatment Outcomes among Patients with Generalized Myasthenia Gravis in the Czech Republic: Results from MYasthenia gravis REGistry (MyReg)
Stanislav Voháňka, Magda Horáková, Qian Cai, Winghan J. Kwong, Kavita Gandhi, Alberto E. Batista, Jana Baranová, Lenka Mokrá, Michaela Týblová, Jana Junkerová, Edvard Ehler, Hana Matulová, Radim Mazanec, Petr Ridzoň, Shane Kavanagh
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.